RxDoctor Payments Data

Missy Dishman, NP

Adult Health · Buffalo, NYNPI 1598223984

Payments from drug & device makers

$5,574in general payments, 2019–2025

Across 259 payments — averaging $21.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$945
  • AbbVie$664
  • AstraZeneca$498
  • E.r. Squibb & Sons, L.L.C.$424
  • Lilly USA, LLC$268
  • Merck$226
  • plus $3K from 43 others

What the payments were for

  • Food & beverage$5,07291%
  • Education$5029%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,574 in reported general payments places this provider in the 90th percentile of 3,828 adult health providers in New York.

See all adult health providers in New York

Medicare billing

Part B allowed, 2024
$306,449
Medicare patients
130
Services billed
39,893

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Lenalidomide48$750,079
RevlimidLenalidomide27$581,257
JakafiRuxolitinib Phosphate34$573,680
ImbruvicaIbrutinib23$365,180
PromactaEltrombopag Olamine28$269,912
EliquisApixaban201$160,117
DopteletAvatrombopag Maleate11$135,955
NplateRomiplostim12$63,999
XareltoRivaroxaban48$53,972
Anastrozole127$2,808
Exemestane21$2,558
Hydroxyurea94$2,536
Letrozole84$1,879
Dexamethasone27$1,003
Acyclovir52$676

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bristol Myers SquibbRevlimid$117$581,25727 claims
Incyte CorporationJakafi$181$573,68034 claims
Pharmacyclics LLC, An Abbvie CompanyImbruvica$58$365,18023 claims
NovartisPromacta$193$269,91228 claims
PfizerEliquis$114$160,117201 claims
AmgenNplate$119$63,99912 claims
Johnson & JohnsonXarelto$945$53,97248 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,828 adult health providers in New York.

Other adult health in Buffalo

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →